Ultrapotent human antibodies protect against SARS-CoV-2 challenge via multiple mechanisms

Cited by (516)

Items 201–300 of 516

1. Posttranslational modifications optimize the ability of SARS-CoV-2 spike for effective interaction with host cell receptors
   Karan Kapoor, Tianle Chen, Emad Tajkhorshid · 2022 · Proceedings of the National Academy of Sciences
2. SARS-CoV-2 Variants, RBD Mutations, Binding Affinity, and Antibody Escape
   Lin Yang, Jiacheng Li, Shuai Guo, Chengyu Hou, Chenchen Liao, Liping Shi, Xiaoliang Ma, Shenda Jiang, Bing Zheng, Yi Fang et al. · 2021 · International Journal of Molecular Sciences
3. SARS-CoV-2 variants impact RBD conformational dynamics and ACE2 accessibility
   Mariana Valério, Luís Borges-Araújo, Manuel N. Melo, Diana Lousa, Cláudio M. Soares · 2022 · Frontiers in Medical Technology
4. Structural basis for receptor binding and broader interspecies receptor recognition of currently circulating Omicron sub-variants
   Zhennan Zhao, Yufeng Xie, Bin Bai, Chunliang Luo, Jingya Zhou, Weiwei Li, Yumin Meng, Linjie Li, Dedong Li, Xiaomei Li et al. · 2023 · Nature Communications
5. RBD trimer mRNA vaccine elicits broad and protective immune responses against SARS-CoV-2 variants
   Qingtai Liang, Yifeng Wang, Shuyuan Zhang, Jing Sun, Wenbo Sun, Jizhou Li, Yaping Liu, Mingxi Li, Lin Cheng, Yuhang Jiang et al. · 2022 · iScience
6. SARS CoV-2 infections in animals, two years into the pandemic
   Sara Frazzini, Massimo Amadori, Lauretta Turin, Federica Riva · 2022 · Archives of Virology
7. Molecular analysis of a public cross-neutralizing antibody response to SARS-CoV-2
   Meng Yuan, Yiquan Wang, Huibin Lv, Timothy J.C. Tan, Ian A. Wilson, Nicholas C. Wu · 2022 · Cell Reports
8. Plant Molecular Farming as a Strategy Against COVID-19 – The Italian Perspective
   Chiara Lico, Luca Santi, Selene Baschieri, Emanuela Noris, Carla Marusic, Marcello Donini, Emanuela Pedrazzini, Giovanni Maga, Rosella Franconi, Paola Di Bonito et al. · 2020 · Frontiers in Plant Science
9. Epitope Profiling Reveals the Critical Antigenic Determinants in SARS-CoV-2 RBD-Based Antigen
   Min Jiang, Gaiping Zhang, Hongliang Liu, Peiyang Ding, Yunchao Liu, Yuanyuan Tian, Yanwei Wang, Aiping Wang · 2021 · Frontiers in Immunology
10. Mapping cross-variant neutralizing sites on the SARS-CoV-2 spike protein
    Shiqi Xu, Yifan Wang, Yanxing Wang, Chao Zhang, Hong Qin, Chenjian Gu, Rong Xu, Tingfeng Wang, Yong Ping Yang, Jinkai Zang et al. · 2021 · Emerging Microbes & Infections
11. Heme binding to the SARS-CoV-2 spike glycoprotein
    Samuel L. Freeman, A. Sofia F. Oliveira, Andrea E. Gallio, Annachiara Rosa, Maria K. Simitakou, Christopher J. Arthur, Adrian John Mulholland, Peter Cherepanov, Emma Lloyd Raven · 2023 · Journal of Biological Chemistry
12. Evolving antibody evasion and receptor affinity of the Omicron BA.2.75 sublineage of SARS-CoV-2
    Qian Wang, Zhiteng Li, Yicheng Guo, Ian A. Mellis, Sho Iketani, Michael Liu, Jian Yu, Riccardo Valdez, Adam S. Lauring, Zizhang Sheng et al. · 2023 · iScience
13. Human antibodies to SARS-CoV-2 with a recurring YYDRxG motif retain binding and neutralization to variants of concern including Omicron
    Hejun Liu, Chengzi I. Kaku, Ge Song, Meng Yuan, Raiees Andrabi, Dennis R. Burton, Laura M. Walker, Ian A. Wilson · 2022 · Communications Biology
14. Structural Immunology of SARS ‐ CoV ‐2
    Meng Yuan, Ian A. Wilson · 2024 · Immunological Reviews
15. Structural and functional characteristics of the SARS-CoV-2 Omicron subvariant BA.2 spike protein
    Jun Zhang, Weichun Tang, Hailong Gao, Christy L. Lavine, Wei Kang Shi, Hanqin Peng, Haisun Zhu, Krishna Anand, Matina Kosikova, Hyung Joon Kwon et al. · 2023 · Nature Structural & Molecular Biology
16. Prophylaxis for COVID-19: a systematic review
    Mikaëla Smit, Annalisa Marinosci, Thomas Agoritsas, Alexandra Calmy · 2021 · Clinical Microbiology and Infection
17. Therapeutic antibodies for COVID-19: is a new age of IgM, IgA and bispecific antibodies coming?
    Jingjing Zhang, Han Zhang, Li-Tao Sun · 2022 · mAbs
18. Shooting at a Moving Target—Effectiveness and Emerging Challenges for SARS-CoV-2 Vaccine Development
    Günl, Franziska, Mecate-Zambrano, Angeles, Rehländer, Selina, Hinse, Saskia, Ludwig, Stephan, Brunotte, Linda · 2021 · Vaccines
19. Impact of the B.1.1.7 variant on neutralizing monoclonal antibodies recognizing diverse epitopes on SARS-CoV-2 Spike
    Graham, Carl, Seow, Jeffrey, Huettner, Isabella, Khan, Hataf, Kouphou, Neophytos, Acors, Sam, Winstone, Helena, Pickering, Suzanne, Galao, Rui Pedro, Lista, Maria Jose et al. · 2021
20. SARS-CoV-2 cell entry and targeted antiviral development
    Zi-Nuo Chen, R. Du, Jazmin M. Galván Achi, Li-Jun Rong, Q. Cui · 2021 · Acta Pharmaceutica Sinica B
21. Exploring the immune evasion of SARS-CoV-2 variant harboring E484K by molecular dynamics simulations
    Leyun Wu, Cheng Peng, Yanqing Yang, Yulong Shi, Liping Zhou, Zhijian Xu, Weiliang Zhu · 2021 · Briefings in Bioinformatics
22. Phage-like particle vaccines are highly immunogenic and protect against pathogenic coronavirus infection and disease
    Bennett Davenport, Alexis Catala, Stuart M. Weston, Robert M. Johnson, Jeremy Ardanuy, Holly Hammond, Carly A. Dillen, Matthew B. Frieman, Carlos Enrique Catalano, Thomas E. Morrison · 2022 · npj Vaccines
23. Combined anti-S1 and anti-S2 antibodies from hybrid immunity elicit potent cross-variant ADCC against SARS-CoV-2
    Michael D. Grant, Kirsten Bentley, Ceri Alan Fielding, Keeley M. Hatfield, Danielle P. Ings, Debbie O. A. Harnum, Eddie C. Y. Wang, Richard James Stanton, Kayla A. Holder · 2023 · JCI Insight
24. Structure-based design of a highly stable, covalently-linked SARS-CoV-2 spike trimer with improved structural properties and immunogenicity
    Eduardo Olmedillas, Colin J. Mann, Wei-Wei Peng, Ying-Ting Wang, Ruben Diaz Avalos, Daniel H. Bedinger, Kristen M. Valentine, N. Shafee, S. Schendel, M. Yuan et al. · 2021 · bioRxiv
25. Subclass-switched anti-spike IgG3 oligoclonal cocktails strongly enhance Fc-mediated opsonization
    Arman Izadi, Arsema Hailu, Magdalena Godzwon, Sebastian Wrighton, Berit Olofsson, Tobias Schmidt, Anna Söderlund‐Strand, Elizabeth Elder, Sofia Appelberg, Maria Valsjö et al. · 2023 · Proceedings of the National Academy of Sciences
26. Membrane lectins enhance SARS-CoV-2 infection and influence the neutralizing activity of different classes of antibodies
    F. Lempp, Leah B. Soriaga, Martin Montiel-Ruiz, F. Benigni, Julia Noack, Young-Jun Park, S. Bianchi, A. Walls, J. Bowen, Jia-Yi Zhou et al. · 2021 · bioRxiv
27. Three immunizations with Novavax’s protein vaccines increase antibody breadth and provide durable protection from SARS-CoV-2
    Klara Lenart, Rodrigo Arcoverde Cerveira, Fredrika Hellgren, Sebastian Ols, Daniel J. Sheward, Changil Kim, Alberto Cagigi, Matthew Gagné, Brandon J. Davis, Daritza Germosen et al. · 2024 · npj Vaccines
28. Discovery and structural optimization of 3-O-β-chacotriosyl oleanane-type triterpenoids as potent entry inhibitors of SARS-CoV-2 virus infections
    Hui Li, Chen Cheng, Sumei Li, Yan Wu, Zhihao Liu, Mingjian Liu, Jianxin Chen, Qiuyu Zhong, Xuesha Zhang, Shuwen Liu et al. · 2021 · European Journal of Medicinal Chemistry
29. A Structure-Based B-cell Epitope Prediction Model Through Combing Local and Global Features
    Shuai Lu, Yuguang Li, Qiang Ma, Xiaofei Nan, Shoutao Zhang · 2022 · Frontiers in Immunology
30. Conformational flexibility in neutralization of SARS-CoV-2 by naturally elicited anti-SARS-CoV-2 antibodies
    Ruofan Li, Michael Mor, Bingting Ma, Alex E. Clark, Joel Alter, Michal Werbner, Jamie Casey Lee, Sandra Lawrynowicz Leibel, Aaron F. Carlin, Moshe Dessau et al. · 2022 · Communications Biology
31. Antibody-mediated immunity to SARS-CoV-2 spike
    John M. Errico, Lucas J. Adams, Daved H. Fremont · 2022 · Advances in immunology
32. The effects of amino acid substitution of spike protein and genomic recombination on the evolution of SARS-CoV-2
    Letian Fang, Jie Xu, Yue Zhao, Junyan Fan, Jiaying Shen, Wenbin Liu, Guangwen Cao · 2023 · Frontiers in Microbiology
33. Structural delineation and computational design of SARS-CoV-2-neutralizing antibodies against Omicron subvariants
    Moriyama, Saya, Anraku, Yuki, Taminishi, Shunta, Adachi, Yu, Kuroda, Daisuke, Kita, Shunsuke, Higuchi, Yusuke, Kirita, Yuhei, Kotaki, Ryutaro, Tonouchi, Keisuke et al. · 2023 · Nature Communications
34. Mucociliary transport deficiency and disease progression in Syrian hamsters with SARS-CoV-2 infection
    Qian Li, Kadambari Vijaykumar, Scott E. Phillips, Shah Saddad Hussain, Nha Van Huynh, Courtney Fernandez Petty, Jacelyn E. Peabody Lever, Jeremy B. Foote, Janna Ren, Javier Campos et al. · 2023 · JCI Insight
35. Structural changes in the SARS-CoV-2 spike E406W mutant escaping a clinical monoclonal antibody cocktail
    Amin Addetia, Young‐Jun Park, Tyler N. Starr, Allison J. Greaney, Kaitlin R. Sprouse, John E. Bowen, Sasha W. Tilles, Wesley C. Van Voorhis A, Jesse D. Bloom, Davide Corti et al. · 2023 · Cell Reports
36. A monoclonal antibody targeting a large surface of the receptor binding motif shows pan-neutralizing SARS-CoV-2 activity
    Leire de Campos‐Mata, Benjamin Trinité, Andrea Modrego, Sonia Tejedor Vaquero, Edwards Pradenas, Anna Pons-Grífols, Natalia Rodrigo Melero, Diego Carlero, Sílvia Marfil, César A. Santiago et al. · 2024 · Nature Communications
37. Structure-guided antibody cocktail for prevention and treatment of COVID-19
    Shih-Chieh Su, Tzu‐Jing Yang, Pei‐Yu Yu, Kang-Hao Liang, Chen Wy, Chun-Wei Yang, Hsiu-Ting Lin, Mei-jung Sebrina Wang, Ruei‐Min Lu, Hsien-Cheng Tso et al. · 2021 · PLoS Pathogens
38. High‐throughput detection of antibodies targeting the SARS‐CoV ‐2 Spike in longitudinal convalescent plasma samples
    Sai Priya Anand, Jérémie Prévost, Jonathan Richard, Josée Perreault, Tony Tremblay, Mathieu Drouin, Marie‐Josée Fournier, Antoine Lewin, Renée Bazin, Andrés Finzi · 2021 · Transfusion
39. Allosteric Control of Structural Mimicry and Mutational Escape in the SARS-CoV-2 Spike Protein Complexes with the ACE2 Decoys and Miniprotein Inhibitors: A Network-Based Approach for Mutational Profiling of Binding and Signaling
    Gennady M. Verkhivker, Steve Agajanian, Deniz Yaşar Öztaş, Grace Gupta · 2021 · Journal of Chemical Information and Modeling
40. Structure–Function Analysis of Resistance to Bamlanivimab by SARS-CoV-2 Variants Kappa, Delta, and Lambda
    Shufeng Liu, Tien Huynh, Charles B. Stauft, Tony T. Wang, Binquan Luan · 2021 · Journal of Chemical Information and Modeling
41. Modeling coronavirus spike protein dynamics: implications for immunogenicity and immune escape
    Genevieve Kunkel, Mohammad Madani, Simon J. White, Paulo H. Verardi, Anna Tarakanova · 2021 · Biophysical Journal
42. A potent human monoclonal antibody with pan-neutralizing activities directly dislocates S trimer of SARS-CoV-2 through binding both up and down forms of RBD
    Xiaofei Wang, Ao Hu, Xiangyu Chen, Yixin Zhang, Fei Yu, Shuai Yue, Arong Li, Junsong Zhang, Zhiwei Pan, Yang Yang et al. · 2022 · Signal Transduction and Targeted Therapy
43. Bovine colostrum-derived antibodies against SARS-CoV-2 show great potential to serve as prophylactic agents
    Kadri Kangro, Mihhail Kurašin, Kiira Gildemann, Eve Sankovski, Eva Žusinaite, Laura Sandra Lello, Raini Pert, Ants Kavak, V. Poikalainen, Lembit Lepasalu et al. · 2022 · PLoS ONE
44. Humoral immunity to SARS-CoV-2 elicited by combination COVID-19 vaccination regimens
    Zijun Wang, Frauke Muecksch, Friederike Münn, Alice Cho, Shuai Zong, Raphael Raspe, Víctor Ramos, Brianna A. Johnson, Tarek Ben Tanfous, Justin DaSilva et al. · 2022 · The Journal of Experimental Medicine
45. Identification of key mutations responsible for the enhancement of receptor-binding affinity and immune escape of SARS-CoV-2 Omicron variant
    Wei Bu Wang, Bo Yi, Ze Hua Lei, Xuefeng Zhang, Jiao Li, Shan Shan Li, Ze Yuan Dong, Yu Liang, Qi Ming Li, Ji Guo Su · 2023 · Journal of Molecular Graphics and Modelling
46. A broadly generalizable stabilization strategy for sarbecovirus fusion machinery vaccines
    Lee, Jimin, Stewart, Cameron, Schäfer, Alexandra, Leaf, Elizabeth M., Park, Young-Jun, Asarnow, Daniel, Powers, John M., Treichel, Catherine, Sprouse, Kaitlin R., Corti, Davide et al. · 2024 · Nature Communications
47. Neutralizing antibody responses over time in demographically and clinically diverse individuals recovered from SARS-CoV-2 infection in the United States and Peru: A cohort study
    Shelly Karuna, Shuying Sue Li, Shannon Grant, Stephen R. Walsh, Ian Frank, Martín Casapía, Meg Trahey, Ollivier Hyrien, Leigh H. Fisher, Maurine D. Miner et al. · 2021 · PLoS Medicine
48. ChAdOx1 nCoV-19 vaccine elicits monoclonal antibodies with cross-neutralizing activity against SARS-CoV-2 viral variants
    Jeffrey Seow, Carl Graham, Sadie R. Hallett, Thomas Lechmere, Thomas J. A. Maguire, Isabella Huettner, Daniel Cox, Hataf Khan, Suzanne Pickering, Rebekah Roberts et al. · 2022 · Cell Reports
49. Application of germline antibody features to vaccine development, antibody discovery, antibody optimization and disease diagnosis
    Yingjie Zhang, Qing Li, Liang Luo, Changfei Duan, Jianzhong Shen, Zhanhui Wang · 2023 · Biotechnology Advances
50. Multi-omics for COVID-19: driving development of therapeutics and vaccines
    Mengyu Guo, Muya Xiong, Jinying Peng, Tong Guan, Haixia Su, Yanyi Huang, Cai‐Guang Yang, Yang Li, Diana Boraschi, Thanigaimalai Pillaiyar et al. · 2023 · National Science Review
51. Mapping immunodominant sites on the MERS-CoV spike glycoprotein targeted by infection-elicited antibodies in humans
    Amin Addetia, Cameron Stewart, Albert J. Seo, Kaitlin R. Sprouse, Ayed Y. Asiri, Maha Al-Mozaini, Ziad Ahmed Memish, Abeer N. Alshukairi, David Veesler · 2024 · Cell Reports
52. Neutralisation titres against SARS-CoV-2 are sustained 6 months after onset of symptoms in individuals with mild COVID-19
    Alexander P. Underwood, Christina Søhoel Sølund, Carlota Fernandez-Antunez, Signe Lysemose Villadsen, Anni Assing Winckelmann, Signe Bollerup, Lotte S. Mikkelsen, Anna-Louise Sørensen, Shan Feng, Ulrik Fahnøe et al. · 2021 · EBioMedicine
53. Dynamic Interactions of Fully Glycosylated SARS-CoV-2 Spike Protein with Various Antibodies
    Yiwei Cao, Yeol Kyo Choi, Martin Frank, Hyeonuk Woo, Sang‐Jun Park, Min Sun Yeom, Chaok Seok, Wonpil Im · 2021 · Journal of Chemical Theory and Computation
54. Evasion of neutralizing antibodies by Omicron sublineage BA.2.75
    Daniel J. Sheward, Changil Kim, Julian Fischbach, Sandra Muschiol, Roy A. Ehling, Niklas K. Björkström, Gunilla B. Karlsson Hedestam, Sai T. Reddy, Jan Albert, Thomas P. Peacock et al. · 2022 · bioRxiv (Cold Spring Harbor Laboratory)
55. Computational Analysis of Mutations in the Receptor-Binding Domain of SARS-CoV-2 Spike and Their Effects on Antibody Binding
    Marine E. Bozdaganyan, Olga S. Sokolova, К. В. Шайтан, Mikhail P. Kirpichnikov, Philipp S. Orekhov · 2022 · Viruses
56. Design of customized coronavirus receptors
    Peng Liu, Meiling Huang, Hua Guo, Matthew McCallum, Jun-Yu Si, Yuanmei Chen, Chunli Wang, Yu Xiao, Lulu Shi, Qing Xiong et al. · 2024 · Nature
57. Structural basis for broad sarbecovirus neutralization by a human monoclonal antibody
    M. Alejandra Tortorici, Nadine Czudnochowski, Tyler N. Starr, Roberta Marzi, Alexandra C. Walls, Fabrizia Zatta, John E. Bowen, Stefano Jaconi, Julia di Iulio, Zhaoqian Wang et al. · 2021 · bioRxiv (Cold Spring Harbor Laboratory)
58. Antibodies to the SARS-CoV-2 receptor-binding domain that maximize breadth and resistance to viral escape
    Tyler N. Starr, Nadine Czudnochowski, Fabrizia Zatta, Young‐Jun Park, Zhuoming Liu, Amin Addetia, Dora Pinto, Martina Beltramello, Patrick Hernandez, Allison J. Greaney et al. · 2021 · bioRxiv (Cold Spring Harbor Laboratory)
59. SARS-CoV-2 spike conformation determines plasma neutralizing activity
    John E. Bowen, Alexandra C. Walls, Anshu Joshi, Kaitlin R. Sprouse, Cameron Stewart, M. Alejandra Tortorici, Nicholas Franko, Jennifer K. Logue, Ignacio G. Mazzitelli, Sasha W. Tilles et al. · 2021 · bioRxiv (Cold Spring Harbor Laboratory)
60. Drug discovery and development targeting the life cycle of SARS-CoV-2
    H. Su, Yechun Xu, Hua-Liang Jiang · 2021 · Fundamental Research
61. A human antibody of potent efficacy against SARS-CoV-2 in rhesus macaques showed strong blocking activity to B.1.351
    Chunyin Gu, Xiaodan Cao, Zongda Wang, Xue Hu, Yanfeng Yao, Yiwu Zhou, Peipei Liu, Xiaowu Liu, Ge Gao, Xiao Hu et al. · 2021 · mAbs
62. Potent Molecular Feature-based Neutralizing Monoclonal Antibodies as Promising Therapeutics Against SARS-CoV-2 Infection
    Arnaud John Kombe Kombe, Ayesha Zahid, Ahmed Mohammed, Ronghua Shi, Tengchuan Jin · 2021 · Frontiers in Molecular Biosciences
63. SARS-CoV-2-related pangolin coronavirus exhibits similar infection characteristics to SARS-CoV-2 and direct contact transmissibility in hamsters
    Zhen-Dong Guo, Cheng Zhang, Chunmao Zhang, Huan Cui, Zhaoliang Chen, Xinyun Jiang, Tie-Cheng Wang, Yuan-Guo Li, Jun Liu, Zhonghai Wan et al. · 2022 · iScience
64. Novel Drug Design for Treatment of COVID-19: A Systematic Review of Preclinical Studies
    Sarah Mousavi, Shima Zare, Mahmoud Mirzaei, Awat Feizi · 2022 · Canadian Journal of Infectious Diseases and Medical Microbiology
65. Comprehensive Overview of Broadly Neutralizing Antibodies against SARS-CoV-2 Variants
    Lingyan Cui, Tingting Li, Wenhui Xue, Sibo Zhang, Hong Wang, Hongjing Liu, Ying Gu, Ningshao Xia, Shaowei Li · 2024 · Viruses
66. When the Dust Has Settled: Calculation of Binding Affinities from First Principles for SARS-CoV-2 Variants with Quantitative Accuracy
    Emma Goulard Coderc de Lacam, Marharyta Blazhynska, Haochuan Chen, James C. Gumbart, Christophe J. Chipot · 2022 · Journal of Chemical Theory and Computation
67. A broadly reactive antibody targeting the N-terminal domain of SARS-CoV-2 spike confers Fc-mediated protection
    L. Adams, Laura A. VanBlargan, Zhuo-Ming Liu, P. Gilchuk, Hai-Yan Zhao, Rita E. Chen, S. Raju, Zhen-Lu Chong, Bradley M. Whitener, S. Shrihari et al. · 2023 · Cell Reports Medicine
68. Rapid and accurate agglutination-based testing for SARS-CoV-2 antibodies
    Sally Esmail, Michael J. Knauer, Husam Abdoh, Courtney Voss, Benjamin Hull Chin-Yee, P.J. Stogios, Almagul Seitova, Ashley Hutchinson, Farhad Yusifov, T. Skarina et al. · 2021 · Cell Reports Methods
69. Analysis of a SARS-CoV-2 convalescent cohort identified a common strategy for escape of vaccine-induced anti-RBD antibodies by Beta and Omicron variants
    Matthew Chang, Hanzhong Ke, Christian D. Coherd, Yufei Wang, Kiyomi Mashima, Gabriella M. Kastrunes, Chiung‐Yu Huang, Wayne Anthony Marasco · 2022 · EBioMedicine
70. Antibody-Based Immunotherapeutic Strategies for COVID-19
    Jamal Hussen, Mahmoud K Kandeel, Maged Gomaa Hemida, Abdullah I. A. Al-Mubarak · 2020 · Pathogens
71. Protein engineering responses to the COVID-19 pandemic
    Ching-Lin Hsieh, J. McLellan · 2022 · Current Opinion in Structural Biology
72. Acquisition of Furin Cleavage Site and Further SARS-CoV-2 Evolution Change the Mechanisms of Viral Entry, Infection Spread, and Cell Signaling
    Elena I. Frolova, Oksana Palchevska, Tetyana Lukash, Francisco de Borja Pérez Domínguez, William J. Britt, Ilya V. Frolov · 2022 · Journal of Virology
73. De novo design and Rosetta‐based assessment of high‐affinity antibody variable regions (Fv) against the SARS‐CoV ‐2 spike receptor binding domain ( RBD )
    Veda Sheersh Boorla, Ratul Chowdhury, Ranjani Ramasubramanian, Brandon Ameglio, Rahel Frick, Jeffrey J. Gray, Costas D. Maranas · 2022 · Proteins Structure Function and Bioinformatics
74. Structural and computational design of a SARS-CoV-2 spike antigen with improved expression and immunogenicity
    James A. Williams, Marco Biancucci, Laura N. Lessen, Sai Tian, Ankita Balsaraf, Lynn Chen, Chelsy C. Chesterman, Giulietta Maruggi, Sarah Vandepaer, Ying Huang et al. · 2023 · Science Advances
75. Conserved Neutralizing Epitopes on the N-Terminal Domain of Variant SARS-CoV-2 Spike Proteins
    Zi-Jun Wang, Frauke Muecksch, Alice Cho, C. Gaebler, H. Hoffmann, Victor A. Ramos, Shuaizhou Zong, M. Cipolla, Bryant Johnson, Fabian Schmidt et al. · 2022 · bioRxiv
76. Ultrapotent class I neutralizing antibodies post Omicron breakthrough infection overcome broad SARS-CoV-2 escape variants
    Mengxiao Luo, Runhong Zhou, Bingjie Tang, Hang Liu, Bo‐Hao Chen, Na Liu, Yufei Mo, Pengfei Zhang, Ye Lim Lee, Jonathan Daniel Ip et al. · 2024 · EBioMedicine
77. Discovery and Characterization of Spike N‐Terminal Domain‐Binding Aptamers for Rapid SARS‐CoV‐2 Detection
    Nataly A. Kacherovsky, Lucy F. Yang, Ha V. Dang, Emmeline L. Cheng, Ian I. Cardle, Alexandra C. Walls, Matthew McCallum, Drew L. Sellers, Frank DiMaio, Stephen J. Salipante et al. · 2021 · Angewandte Chemie
78. Structural and Computational Studies of the SARS-CoV-2 Spike Protein Binding Mechanisms with Nanobodies: From Structure and Dynamics to Avidity-Driven Nanobody Engineering
    Gennady M. Verkhivker · 2022 · International Journal of Molecular Sciences
79. Structural analysis of receptor engagement and antigenic drift within the BA.2 spike protein
    James W. Saville, Dhiraj Mannar, Xing Quan Zhu, Alison Berezuk, Spencer CHOLAK, Katherine R. Tuttle, Faezeh Vahdati Hassani, Sriram Subramaniam · 2023 · Cell Reports
80. The role of S477N mutation in the molecular behavior of SARS‐CoV‐2 spike protein: An in‐silico perspective
    Mozhgan Mondeali, Ali Etemadi, Khabat Barkhordari, Mina Mobini Kesheh, Sara Shavandi, Atefeh Bahavar, Fatemeh Hosseini, Mohammad Mahmoudi Gomari, Mohammad Hossein Modarressi · 2023 · Journal of Cellular Biochemistry
81. A nanobody recognizes a unique conserved epitope and potently neutralizes SARS-CoV-2 omicron variants
    Naphak Modhiran, Simon Malte Lauer, Alberto Anastacio Amarilla, Peter Hewins, Sara Lopes van den Broek, Yu Shang Low, Nazia Thakur, Benjamin Liang, Guillermo Valenzuela, James Jung et al. · 2023 · iScience
82. Structural and energetic profiling of SARS-CoV-2 receptor binding domain antibody recognition and the impact of circulating variants
    Rui Ming Yin, Johnathan D. Guest, Ghazaleh Taherzadeh, Ragul Gowthaman, Ipsa Mittra, Jane Quackenbush, Brian G. Pierce · 2021 · PLoS Computational Biology
83. Computer Simulations and Network-Based Profiling of Binding and Allosteric Interactions of SARS-CoV-2 Spike Variant Complexes and the Host Receptor: Dissecting the Mechanistic Effects of the Delta and Omicron Mutations
    Gennady M. Verkhivker, Steve Agajanian, Ryan Kassab, Keerthi Krishnan · 2022 · International Journal of Molecular Sciences
84. Cell-based reporter assays for measurements of antibody-mediated cellular cytotoxicity and phagocytosis against SARS-CoV-2 spike protein
    Yuting Hong, Huilin Guo, Min Wei, Yali Zhang, Mujin Fang, Tong Cheng, Zhiyong Li, Shengxiang Ge, Xiangyang Yao, Quan Yuan et al. · 2022 · Journal of Virological Methods
85. Analysis of the molecular mechanism of SARS-CoV-2 antibodies
    Dongfu Jin, Jing Wei, Jian Sun · 2021 · Biochemical and Biophysical Research Communications
86. A potent neutralizing antibody provides protection against SARS-CoV-2 Omicron and Delta variants via nasal delivery
    Xinghai Zhang, Huajun Zhang, Tingting Li, Shaohong Chen, Feiyang Luo, Junhui Zhou, Peiyi Zheng, Shuyi Song, Yan Wu, Tengchuan Jin et al. · 2022 · Signal Transduction and Targeted Therapy
87. Multimeric nanobodies from camelid engineered mice and llamas potently neutralize SARS-CoV-2 variants
    Jianliang Xu, Kai Y. Xu, Seolkyoung Jung, A. Conte, Jenna Ariel Lieberman, Frauke Muecksch, Julio C. C. Lorenzi, Solji Park, Zijun Wang, Lino Tessarollo et al. · 2021 · bioRxiv (Cold Spring Harbor Laboratory)
88. Novel super-neutralizing antibody UT28K is capable of protecting against infection from a wide variety of SARS-CoV-2 variants
    Tatsuhiko Ozawa, Hideki Tani, Yuki Anraku, Shunsuke Kita, Emiko Igarashi, Yumiko Saga, Noriko Inasaki, Hitoshi Kawasuji, Hiroshi Yamada, Soichiro Sasaki et al. · 2022 · mAbs
89. Convergence of immune escape strategies highlights plasticity of SARS-CoV-2 spike
    Xiaodi Yu, Jarek Juraszek, Lucy Rutten, Mark J. G. Bakkers, Sven Blokland, Jelle M. Melchers, Niels J. F. van den Broek, Annemiek Verwilligen, Pravien D. Abeywickrema, Johan Vingerhoets et al. · 2023 · PLoS Pathogens
90. Broad Sarbecovirus Neutralizing Antibodies Obtained by Computational Design and Synthetic Library Screening
    Xuehua Yang, Huarui Duan, Xiuying Liu, Xinhui Zhang, Shengnan Pan, Fangyuan Zhang, Peixiang Gao, Бо Лю, Jian Yang, Xiaojing Chi et al. · 2023 · Journal of Virology
91. The post-COVID-19 population has a high prevalence of cross-reactive antibodies to spikes from all Orthocoronavirinae genera
    Gagandeep Singh, Anass Abbad, Giulio Kleiner, Komal Srivastava, Charles Gleason, PARIS Study Group, Juan Manuel Carreño, Viviana R. Simon, Florian Krammer, Dalles Andre et al. · 2023 · mBio
92. Relevance of BET Family Proteins in SARS-CoV-2 Infection
    Nieves Lara-Ureña, Mario García‐Domínguez · 2021 · Biomolecules
93. Analysis of Neutralization Titers against SARS-CoV-2 in Health-Care Workers Vaccinated with Prime-Boost mRNA–mRNA or Vector–mRNA COVID-19 Vaccines
    Christina Søhoel Sølund, Alexander P. Underwood, Carlota Fernandez-Antunez, Signe Bollerup, Lotte S. Mikkelsen, Signe Lysemose Villadsen, Ulrik Fahnøe, Anni Assing Winckelmann, Shan Feng, Caroline Vinten et al. · 2022 · Vaccines
94. Landscape-Based Protein Stability Analysis and Network Modeling of Multiple Conformational States of the SARS-CoV-2 Spike D614G Mutant: Conformational Plasticity and Frustration-Induced Allostery as Energetic Drivers of Highly Transmissible Spike Variants
    Gennady M. Verkhivker, Steve Agajanian, Ryan Kassab, Keerthi Krishnan · 2022 · Journal of Chemical Information and Modeling
95. Neutralizing and enhancing antibodies against SARS-CoV-2
    Yafei Liu, Hisashi Arase · 2022 · Inflammation and Regeneration
96. Effect of Double Mutation (L452R and E484Q) on the Binding Affinity of Monoclonal Antibodies (mAbs) against the RBD—A Target for Vaccine Development
    Deepali Gupta, Mukesh Kumar, Priyanka Sharma, Trishala Mohan, Amresh Prakash, Renu Kumari, Punit Kaur · 2022 · Vaccines
97. Advances in nanobiosensors during the COVID-19 pandemic and future perspectives for the post-COVID era
    Young Jun Kim, Junhong Min · 2024 · Nano Convergence
98. Coronavirus disease 2019 and the revival of passive immunization: Antibody therapy for inhibiting severe acute respiratory syndrome coronavirus 2 and preventing host cell infection: IUPHAR review 31
    Francesca Levi‐Schaffer, Ario de Marco · 2021 · British Journal of Pharmacology
99. Comparative immunogenicity analysis of intradermal versus intramuscular administration of SARS-CoV-2 RBD epitope peptide-based immunogen In vivo
    Naveen Yadav, Preeti Vishwakarma, Ritika Khatri, Gazala Siddqui, Amit Awasthi, Shubbir Ahmed, Sweety Samal · 2021 · Microbes and Infection
100. Cyclophilin A‐mediated mitigation of coronavirus SARS‐CoV ‐2
     Simranjeet Singh Sekhon, Woo‐Ri Shin, Sang Yong Kim, Dong‐Seok Jeong, Wooil Choi, Bong‐Keun Choi, Jiho Min, Ji‐Young Ahn, Yang‐Hoon Kim · 2022 · Bioengineering & Translational Medicine